TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-t of sotalol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Urine Samples Negative for Cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of blood products used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount of perioperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in straight line deviation (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of induction treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the MHISS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete Hematological Response (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With a Complete Response (CR) or Unconfirmed CR (CRu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With a CR, CRu or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants in viral failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BMI of participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Uracil levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 4-Hydroxyproline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Creatine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glutamic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood nutrient levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamic Functional Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Develop Postoperative Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Participants no Longer Meeting Criteria for Severe Aplastic Anemia
Endpoint domain: Mortality/survival
Primary endpoint: Positive Predictive Value of Digital ABI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 4M PFS Rate
Endpoint domain: Mortality/survival
Primary endpoint: Immunological responses upon vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toxicity of TLR-DC and Trimix-DC
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of escalating doses ON01910.Na
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 2-Gene Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angular velocity and acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electrical activity produced by the muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Elapsed time engaged in specific hospital work activities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Knowledge about broad sharing of genetic data
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability of broad sharing of genetic data
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle carnitine uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: First analgesia rescue call
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of improvement of picture naming
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Internet Use Disorder 12-months incidence rate (Clinical Interview for DSM-5 Diagnosis)
Endpoint domain: Mortality/survival
Primary endpoint: Internet Use Disorder 12-months incidence rate (Self-Report)
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Internet Use Disorder prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Change in fruit and vegetable consumption
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Rate of Patients With Actionable Alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Baseline Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PD-L1 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lapatinib Ditosylate Intratumoral Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Phosphorylated (p)EGFR/Total EGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of patients having osteomyelitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients with arrhythmia recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain intensity with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of HIV acquisition
Endpoint domain: Adverse events/effects
Primary endpoint: AUClast, 480
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV Treatment Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with locoregional tumour control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with bleeding or perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Adequate dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 3-month Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: HBsAg loss/seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Running biomechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) of LY2409021
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Drug Concentration (Tmax) of LY2409021
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent reduction in plasma low-density lipoprotein cholesterol (LDL-C) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of peak oxygen consumption (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Migraine Headache Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological suppression measured by HIV-1 RNA ≥50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage Change in Ki-67 Labelling Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gynecological Cancer Sexual Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gynecological Cancer Sexual Attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gynecological Cancer Sexual self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diversity of Sexual Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Mean Highest-Average-Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPAP adherence in minutes used per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture displacement as measured by Baumann Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fracture angulation as measured by Shaft Condylar Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of dysrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in score on the Roland-Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Virologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serological responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with SBP below lower limit of target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients reaching prespecified target SBP range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optical detection of HCMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics parameters of salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Value of I-FABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: RBC saturation of Omega-3 fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IOP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in QTcI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low Back Pain Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Straight Leg Raise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained return of spontaneous circulation (ROSC)
Endpoint domain: Mortality/survival
Primary endpoint: survival at hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Initiation of HPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative Room Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of atopic dermatitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with improvement or worsening of atopic dermatitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence acceptance range of AUC and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glasgow Coma Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: oxycodone consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HbA1C at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in static sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State of anxiety assessed by Face Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response probability (confirmed complete and confirmed partial responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Test Score of 6 Minute Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Test Score of 30-second Chair Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Test Score of 8-Foot Up-and-Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's satisfaction with pain treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse drug reactions and toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Staging accuracy of PET-CT with 18F-FDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average carotid artery intima-media thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-month target vessel failure (TVF) rate
Endpoint domain: Mortality/survival
Primary endpoint: device procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity in cardiac sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of anti-asparaginase antibody
Endpoint domain: Adverse events/effects
Primary endpoint: pain following lap hernioplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Falls
Endpoint domain: Adverse events/effects
Primary endpoint: serum miRNA after parathyroidectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of morphine analgesic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serotype-specific antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intent to Discuss Advance Directives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intent to Discuss Medical Power of Attorney
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intent to Discuss Palliative Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intent to Discuss Hospice Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24h Energy Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in episodic memory functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive predictor of falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with newly diagnosed hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with confirmed primary aldosteronism (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Usefulness of Glow800 Technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of healthcare-associated infection
Endpoint domain: Adverse events/effects
Primary endpoint: HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative blood flow changes of the oral mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean percent change in Psoriasis Area and Severity Index (PASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Behavior Rating Inventory of Executive Function Second Edition (BRIEF 2) - change at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavior Rating Inventory of Executive Function Second Edition (BRIEF 2) - change at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: hospitalization due to worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: administration of IV drug therapy for worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Indirect blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Spinal curve and mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to occurrence of in-stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in inspiratory peak flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Marrow adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic Efficacy (viral load <50 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Focused Examination of the Head and Neck Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery and Asberg Depression Rating Scale (MADRS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS-score (calcaneal fractures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of foot examination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: assessment of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of the depression patients diagnosed with BMS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of the sleepiness patients diagnosed with BMS
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Feasibility as measured by rate of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of adverse events CTC-AE
Endpoint domain: Adverse events/effects
Primary endpoint: Pain measured using KOOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of disease relapse
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients With Cardiogenic Shock or Respiratory Failure From Pulmonary Embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number With Major Hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Number With Functional Cardiopulmonary Limitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number With Recurrent Venous Thromboembolism and/or Severe Post-phlebitic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: QTcF interval duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight of diaper test (grams)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of involuntary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of vibration in external sphincter (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AL-335 and its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of AL-335 and its Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Odalasvir (ODV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pediatric AML miR expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in biological behavior of AML cells (dormant versus invasive)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching low disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-Persistence in wAMD therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of blood flow (peak systolic velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Basal testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Annualized Rate of Moderate to Severe Acute Exacerbation Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Level of proteins in circulating blood and muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of metabolites in circulating blood and muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of mRNA in circulating blood and muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of DNA methylation in cardiac muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Korean Boston naming test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Korean Western Aphasia Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immunogenic response measured by anti-PRP antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 3-D motion Analysis- sit to stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes